financetom
Business
financetom
/
Business
/
Cidara Therapeutics Expects to Raise $105 Million From Private Placement
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cidara Therapeutics Expects to Raise $105 Million From Private Placement
Nov 21, 2024 10:07 AM

09:35 AM EST, 11/21/2024 (MT Newswires) -- Cidara Therapeutics ( CDTX ) said Thursday it has agreed to a private placement expected to raise about $105 million.

Under the agreement, Cidara will issue about 3.9 million shares of common stock at $14.912 per share, the company said. Additionally, certain investors will purchase about 3.2 million pre-funded warrants at $14.9119 each, with an exercise price of $0.0001 per warrant, the company added.

The company said the financing, led by Venrock Healthcare Capital Partners, includes participation from new and existing investors like RA Capital Management among others.

Net proceeds from the placement, expected to close by Nov. 25, will be used to advance research and development, support working capital needs, and cover general corporate expenses, Cidara said.

Shares of the company were up 25% in early Wednesday trading.

Price: 18.86, Change: +3.74, Percent Change: +24.75

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Aramco To Acquire 50% Stake In Air Products Qudra's Blue Hydrogen Industrial Gases
BRIEF-Aramco To Acquire 50% Stake In Air Products Qudra's Blue Hydrogen Industrial Gases
Jul 16, 2024
July 16 (Reuters) - SAUDI ARABIAN OIL CO: * ARAMCO TO ACQUIRE 50% STAKE IN AIR PRODUCTS QUDRA'S BLUE HYDROGEN INDUSTRIAL GASES * ARAMCO, AIR PRODUCTS QUDRA JOIN FORCES TO DEVELOP LOWER-CARBON HYDROGEN PRODUCTION BUSINESS * AGREEMENT AIMS TO SUPPORT GROWTH OF ARAMCO'S NEW ENERGIES PORTFOLIO * UPON COMPLETION OF TRANSACTION, ARAMCO AND APQ ARE EXPECTED TO EACH OWN A...
Mangoceuticals Secures DEA Approval For HIPAA-Compliant Operating System via Surescripts
Mangoceuticals Secures DEA Approval For HIPAA-Compliant Operating System via Surescripts
Jul 16, 2024
10:59 AM EDT, 07/16/2024 (MT Newswires) -- Mangoceuticals ( MGRX ) said Tuesday it received DEA authorization for its HIPAA-compliant operating system through Surescripts. This significant milestone positions MangoRx at the forefront of the direct-to-consumer...telemedicine market, the firm said. The company said the authorization will enable it to expand its offerings to include controlled substances, including hormone replacement therapies, creating...
Perdoceo Education to Acquire University of St. Augustine for Health Sciences
Perdoceo Education to Acquire University of St. Augustine for Health Sciences
Jul 16, 2024
11:00 AM EDT, 07/16/2024 (MT Newswires) -- Perdoceo Education ( PRDO ) said Tuesday that it has entered a definitive deal to acquire the University of St. Augustine for Health Sciences for an expected amount of $142 million to $144 million in cash. If the deal is axed, Perdoceo said it will be liable to pay the seller a termination...
Update: FDA Sets Target Action Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin
Update: FDA Sets Target Action Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin
Jul 16, 2024
10:56 AM EDT, 07/16/2024 (MT Newswires) -- (Adds share price movement in first paragraph). Lexicon Pharmaceuticals ( LXRX ) rose more than 5% after the biopharmaceutical company said Tuesday the US Food and Drug Administration set a Dec. 20 target action date to complete its regulatory review and make a final market decision for its Zynquista (sotagliflozin) diabetes therapy. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved